Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
Merit Medical Systems reported strong fourth quarter and full year 2025 results and issued higher 2026 guidance. Full year 2025 net sales were $1,515.9 million, up 12% from 2024, with GAAP diluted EPS of $2.13 and non-GAAP EPS of $3.83, both increasing year over year.
Profitability improved as GAAP gross margin rose to 48.7% and non-GAAP gross margin to 53.7%, while GAAP operating margin reached 12.2% and non-GAAP operating margin 20.3%. Free cash flow was $215.7 million, up 16%, supported by $297.4 million in operating cash flow and $81.7 million of capital expenditures.
For 2026, Merit guides revenue to $1.610–$1.630 billion, implying 6%–8% growth, and non-GAAP EPS to $4.01–$4.15, 5%–8% above 2025. Management highlights stable constant-currency growth, improving margins, strong cash generation and continued execution of its multi-year growth initiatives program.
Merit Medical Systems, Inc. reported that it has issued a press release with preliminary unaudited revenue for the quarter ended December 31, 2025 and outlined plans to report full fourth-quarter and full-year 2025 results along with fiscal 2026 guidance.
The company also disclosed significant board changes. Longtime leader Fred P. Lampropoulos resigned as a director and Chair of the Board effective January 4, 2026, after previously concluding his service as Executive Chair, President and Chief Executive Officer, citing personal reasons and with no disagreement related to management, the board, or financial reporting and controls. Merit entered into a three-month consulting agreement with him at $250,000 per month. Effective January 5, 2026, the board appointed former Lead Independent Director F. Ann Millner, Ed.D. as Chair and reduced the board size from eleven to ten members.
Merit Medical Systems' chief operating officer Neil W. Peterson reported an option exercise and share sale in company stock. On January 6, 2026, he exercised 5,000 non-qualified stock options with an exercise price of $54.4 per share, receiving 5,000 shares of common stock. The same day, he sold 5,000 common shares at a price of $90 per share, leaving him with 28,369 common shares held directly afterward. The filing also shows remaining non-qualified stock options for 25,000 shares at an exercise price of $68.33 and 13,576 shares at $70.58, all held directly. The option exercise and related sale were carried out under a Rule 10b5-1 trading plan adopted on November 6, 2024.
The issuer filed a Form 144 indicating that a holder plans to sell 5,000 shares of common stock under Rule 144.
The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/06/2026 and an aggregate market value of $450,000. The filing notes that 59,290,248 shares of this class were outstanding.
The 5,000 shares were acquired on 01/06/2026 via a stock option exercise from the issuer, paid for in cash on the same date.
Merit Medical Systems (MMSI) reported an insider transaction by a director and Executive Chairman. On 11/25/2025, the insider sold 10,000 shares of common stock at a weighted average price of $88.0377, with individual trades between $88.00 and $88.175. After the sale, the insider directly owned 1,019,955 shares of common stock.
The insider also had indirect holdings of 8,280.258 shares through a spouse, 98,132 shares through a 401(k) plan as of 10/31/2025, and 90 shares held by the spouse as custodian for a child. In addition, the insider held non-qualified stock options to purchase 100,334 shares at $37.71 expiring on 02/26/2027, 58,083 shares at $56.25 expiring on 03/19/2028, and 54,302 shares at $70.58 expiring on 02/28/2030, each vesting in 25% annual installments from their respective commencement dates.
Merit Medical Systems (MMSI) Executive Chairman and director reported a sale of company stock and detailed his remaining holdings. On 11/21/2025, he sold 25,000 shares of common stock at a weighted average price of $87.31, with individual trades ranging from $87.0000 to $87.6708. After this sale, he directly owns 1,029,955 shares of Merit Medical common stock.
He also reports indirect ownership of 8,280.258 shares held by his spouse, 98,132 shares held in a 401(k) plan as of 10/31/2025, and 90 shares held by his spouse as custodian for a child, while expressly disclaiming beneficial ownership of the spouse’s securities. In addition, he holds non-qualified stock options to purchase 100,334 shares at $37.71 exercisable through 02/26/2027, 58,083 shares at $56.25 through 03/19/2028, and 54,302 shares at $70.58 through 02/28/2030, each vesting in 25% annual installments from their respective commencement dates.
Merit Medical Systems (MMSI) Executive Chairman and director reported an insider stock sale. On 11/20/2025, the reporting person sold 20,000 shares of Merit Medical common stock at a weighted average price of $85.1325 per share. The filing notes that these shares were sold in multiple transactions within a price range from $85.01 to $86.3499 per share.
After this sale, the reporting person directly owned 1,054,955 shares of common stock. In addition, there were indirect holdings of 8,280.258 shares through a spouse, 98,132 shares through a 401(k) plan as of 10/31/2025, and 90 shares held by a spouse as custodian for a child. The report also lists non-qualified stock options with exercise prices between $37.71 and $70.58 covering a total of 212,719 shares, with vesting in equal 25% annual installments beginning on their respective commencement dates.
Merit Medical Systems executive chairman and director reported selling 5,000 shares of common stock on 11/18/2025 at a weighted average price of $84.826 per share. Following this sale, he directly owns 1,074,955 shares, with additional indirect holdings including 8,280.258 shares held by his spouse, 98,132 shares in a 401(k) plan as of 10/31/2025, and 90 shares held by his spouse as custodian for a child.
He also holds non-qualified stock options to purchase 100,334 shares at $37.71 exercisable through 02/26/2027, 58,083 shares at $56.25 exercisable through 03/19/2028, and 54,302 shares at $70.58 exercisable through 02/28/2030, each becoming exercisable in 25% annual installments from their respective commencement dates. The filing notes the spouse’s holdings are disclaimed as beneficial ownership.
Merit Medical Systems furnished a Form 8-K to share a press release with updates on U.S. reimbursement and commercial strategies for its WRAPSODY® Cell-Impermeable Endoprosthesis. The press release is attached as Exhibit 99.1 and provides product-related commercial and reimbursement developments. The disclosure under Item 7.01 is furnished pursuant to General Instruction B.2 and is not deemed “filed” under the Exchange Act, nor incorporated by reference into other filings.
Merit Medical Systems (MMSI) closed the C2 CryoBalloon acquisition. The company reported that on November 3, 2025, it completed the purchase of the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical. The deal follows a definitive asset purchase agreement previously announced.
The disclosure is furnished under Item 7.01 (Regulation FD) and, along with Exhibit 99.1, is not deemed “filed” under the Exchange Act. The company also included a comprehensive safe harbor statement regarding forward-looking statements tied to integration, development, commercialization, and performance outcomes related to the C2 CryoBalloon assets.